JYNT - The Joint reports growth in 2023 operating metrics below 2022 level

2024-01-11 07:18:15 ET

• The Joint ( NASDAQ: JYNT ) has reported increased system-wide sales of 12%, compared to 21% in 2022.
• The company also delivered comp sales of 4%, compared to 9% in 2022.
• Performed 13.6 million patient visits, compared to 12.2 million in 2022.
• Treated 932,000 new patients, compared to 845,000 in 2022.
• Sold 55 franchise licenses, compared to 75 in 2022.
• Expanded total clinic count to 935, up from 838 clinics at December 31, 2022.
• The company will report Q4 financial results on Thursday, March 7, 2024, after the market close.
• Source: Press Release

For further details see: